AR113826A1 - Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) - Google Patents
Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)Info
- Publication number
- AR113826A1 AR113826A1 ARP180103202A ARP180103202A AR113826A1 AR 113826 A1 AR113826 A1 AR 113826A1 AR P180103202 A ARP180103202 A AR P180103202A AR P180103202 A ARP180103202 A AR P180103202A AR 113826 A1 AR113826 A1 AR 113826A1
- Authority
- AR
- Argentina
- Prior art keywords
- nhc
- alkyl
- heterocycloalkyl
- substituted
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Compuesto de fórmula (1), en la que Z es H, D, O(R⁵), CH₃, CºN, Cl, C(=O)NH₂, N(R⁵)(R⁶), N(R⁵)C(=O)(R⁶), NHC(=O)N(R⁵)(R⁶), N(R⁵)SO₂(R⁶), NHC(=O)C(=O)O(R⁵), NHC(=O)C(=O)N(R⁵)(R⁶), NHC(=O)NHSO₂R⁵, CH₂-N(R⁵)(R⁶) o heteroarilo; R¹ es H, D, F, Cl, Br o NH₂; R² se selecciona, para cada posición, independientemente del grupo que comprende H, CF₂H, CF₃, CF₂CH₃, F, Cl, Br, CH₃, Et, i-Pr, c-Pr, D, CH₂OH, CH(CH₃)OH, CH₂F, C(F)CH₃, I, C=C, CºC, CºN, C(CH₃)₂OH, Si(CH₃)₃, SMe, OH y OCH₃; R³ y R⁴ se seleccionan, para cada posición, independientemente del grupo que comprende H, metilo y etilo, R³ y R⁴ están opcionalmente conectados para formar un anillo cicloalquilo C₃₋₅; R⁵ y R⁶ se seleccionan independientemente del grupo que comprende H, D, alquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo C₄₋₇, aminoalquilo C₂₋₆ y hidroxialquilo C₂₋₆, opcionalmente sustituido con 1, 2 ó 3 grupos, cada uno seleccionado independientemente de OH, halo, CºN, acilo, SO₂Me, carboxi, éster de carboxilo, carbamoílo, carbamoílo sustituido, arilo C₆, heteroarilo, alquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo C₃₋₇, heterocicloalquilo C₃₋₇ sustituido con acilo o éster de carboxilo, haloalquilo C₁₋₆, alcoxi C₁₋₆, alquil C₁₋₆-O-alquilo C₁₋₆, hidroxialquilo C₁₋₆, alquilamino C₁₋₆ y alqueniloxi C₁₋₆, R⁵ y R⁶ están opcionalmente conectados para formar un anillo heterocíclico C₄₋₇ que contiene 1 ó 2 átomos de nitrógeno u oxígeno, opcionalmente sustituido con 1, 2 ó 3 grupos, cada uno seleccionado independientemente de OH, halo, acilo, SO₂Me, carboxi, éster de carboxilo, carbamoílo, carbamoílo sustituido, arilo C₆, heteroarilo, alquilo C₁₋₆, cicloalquilo C₃₋₆, heterocicloalquilo C₃₋₇, haloalquilo C₁₋₆, alcoxi C₁₋₆, hidroxialquilo C₁₋₆, y alqueniloxi C₁₋₆; n es 1 ó 2; m es 0 ó 1; a condición de que cuando Z es NHC(=O)N(R⁵)(R⁶), ni R⁵ ni R⁶ es ciclopentilo o isopropilo y cuando Z es N(R⁵)C(=O)(R⁶) y R⁵ es H, R⁶ no es ciclopropilo no sustituido, ciclobutilo no sustituido, CH₃, o tetrahidrofuranilo; o una sal farmacéuticamente aceptable del mismo o un solvato o un hidrato de un compuesto de fórmula (1) o la sal farmacéuticamente aceptable del mismo o un profármaco de un compuesto de fórmula (1) o una sal farmacéuticamente aceptable o un solvato o un hidrato del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17199687 | 2017-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR113826A1 true AR113826A1 (es) | 2020-06-17 |
Family
ID=60201941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180103202A AR113826A1 (es) | 2017-11-02 | 2018-11-02 | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11267825B2 (es) |
| EP (1) | EP3704127A1 (es) |
| JP (1) | JP2021501764A (es) |
| KR (1) | KR20200083551A (es) |
| CN (1) | CN111448199A (es) |
| AR (1) | AR113826A1 (es) |
| AU (1) | AU2018361364B2 (es) |
| BR (1) | BR112020008762A2 (es) |
| CA (1) | CA3081386A1 (es) |
| CL (1) | CL2020001145A1 (es) |
| CU (1) | CU20200037A7 (es) |
| EA (1) | EA202091113A1 (es) |
| EC (1) | ECSP20029558A (es) |
| GE (2) | GEAP202115351A (es) |
| IL (1) | IL274298A (es) |
| MA (1) | MA50524A (es) |
| MX (1) | MX2020004839A (es) |
| PH (1) | PH12020550525A1 (es) |
| SG (1) | SG11202003700TA (es) |
| TW (1) | TW201930315A (es) |
| UY (1) | UY37962A (es) |
| WO (1) | WO2019086141A1 (es) |
| ZA (1) | ZA202002249B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38436A (es) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| UY38434A (es) * | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| US20220306647A1 (en) * | 2019-04-30 | 2022-09-29 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitus b virus (hbv) |
| US20230028318A1 (en) * | 2019-11-08 | 2023-01-26 | President And Fellows Of Harvard College | Fluorogenic amino acids |
| CA3202764A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| US12006291B2 (en) | 2022-01-11 | 2024-06-11 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| CN116068100A (zh) * | 2022-11-24 | 2023-05-05 | 上海研诺医药科技有限公司 | 一种测定4-羟乙基哌嗪乙磺酸的检测方法 |
| CN116396204B (zh) * | 2023-03-29 | 2024-09-24 | 无锡科华生物科技有限公司 | 一种4,6,7-三氟-1h-吲哚-2-羧酸的制备方法 |
| CN117886810A (zh) * | 2023-12-18 | 2024-04-16 | 徐州医科大学 | 一种吲哚啉类化合物及其制备方法和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6290998A (en) | 1997-03-07 | 1998-09-29 | Novo Nordisk A/S | 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| AU4289100A (en) | 1999-03-25 | 2000-10-16 | Bayer Aktiengesellschaft | Dihydropyrimidines and their use in the treatment of hepatitis |
| WO2001045712A1 (de) | 1999-12-22 | 2001-06-28 | Bayer Aktiengesellschaft | Arzneimittelkombinationen gegen virale erkrankungen |
| DE10012823A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| CA2773066A1 (en) | 2003-11-12 | 2005-05-26 | Daiichi Sankyo Company, Limited | Process for producing thiazole derivative |
| WO2006033995A2 (en) | 2004-09-16 | 2006-03-30 | Valeant Research And Development | Thiazolidin-4-ones having anti-hepatitis b activity |
| EP1998620B1 (en) | 2006-03-10 | 2011-01-12 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
| WO2008085118A1 (en) | 2007-01-12 | 2008-07-17 | Astrazeneca Ab | Pyridine compounds and their use as p2y12 antagonists. |
| ES2445199T3 (es) | 2008-06-05 | 2014-02-28 | Glaxo Group Limited | Derivados de benzpirazol como inhibidores de PI3-quinasas |
| US8024013B2 (en) | 2008-07-09 | 2011-09-20 | Sony Ericsson Mobile Communications Ab | Regulating power duty cycle of an RF transmitter/receiver responsive to distance moved |
| EP2327704A4 (en) | 2008-08-29 | 2012-05-09 | Shionogi & Co | RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT |
| CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| EP2611298A4 (en) * | 2010-08-31 | 2014-07-30 | Univ Vanderbilt | BICYCLIC OXAZOLE AND THIAZOL COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR-5 RECEPTORS |
| SI2611444T1 (sl) | 2010-09-02 | 2016-04-29 | Suven Life Sciences Limited Serene Chambers | Spojine heterociklila kot ligandi receptorja histamina H3 |
| EP2720695A4 (en) | 2011-06-15 | 2014-11-12 | Nono Inc | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES |
| EP3085368A1 (en) | 2011-07-01 | 2016-10-26 | Baruch S. Blumberg Institute | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| MD20140044A2 (ro) | 2011-11-11 | 2014-08-31 | Pfizer Inc. | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare |
| JP5977837B2 (ja) | 2011-12-21 | 2016-08-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス剤 |
| AR089671A1 (es) | 2012-01-06 | 2014-09-10 | Janssen R & D Ireland | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| NZ743463A (en) | 2012-08-28 | 2019-09-27 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| AU2013307328B2 (en) | 2012-08-28 | 2017-10-19 | Janssen Sciences Ireland Uc | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US9695178B2 (en) | 2013-01-15 | 2017-07-04 | Suzhou Kintor Pharmaceuticals, Inc. | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| US9266904B2 (en) | 2013-05-17 | 2016-02-23 | Hoffmann-La Roche Inc. | 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection |
| CN105960400B (zh) | 2013-05-17 | 2019-05-31 | 爱尔兰詹森科学公司 | 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| CA2927560A1 (en) | 2013-10-18 | 2015-04-23 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
| ES2777248T3 (es) | 2013-11-14 | 2020-08-04 | Novira Therapeutics Inc | Derivados de azepano y métodos de tratar infecciones por hepatitis B |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| PT3114128T (pt) | 2014-03-07 | 2019-02-27 | Hoffmann La Roche | Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b. |
| SG10202001506UA (en) | 2014-03-13 | 2020-04-29 | Univ Indiana Res & Tech Corp | Hepatitis b core protein allosteric modulators |
| MX2016012573A (es) | 2014-03-28 | 2018-02-19 | Sunshine Lake Pharma Co Ltd | Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos. |
| CA2948580A1 (en) | 2014-05-09 | 2015-11-12 | Adam Zlotnick | Methods and compositions for treating hepatitis b virus infections |
| WO2016023877A1 (en) | 2014-08-14 | 2016-02-18 | F. Hoffmann-La Roche Ag | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection |
| JP2018504373A (ja) | 2014-12-02 | 2018-02-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｈｂｖ治療用のスルフィドアルキル及びピリジルリバーススルホンアミド化合物 |
| WO2016109684A2 (en) | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| MA41338B1 (fr) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| CN107427514B (zh) | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
| EP3292120B1 (en) | 2015-05-04 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections |
| US10738035B2 (en) | 2015-05-13 | 2020-08-11 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP6598974B2 (ja) | 2015-07-21 | 2019-10-30 | エフ．ホフマン−ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症の治療および予防のための新規な三環式４−ピリドン−３−カルボン酸誘導体 |
| WO2017015451A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| TW201720802A (zh) | 2015-09-15 | 2017-06-16 | 艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| HK1259410A1 (zh) | 2015-09-29 | 2019-11-29 | 诺维拉治疗公司 | 乙型肝炎抗病毒剂的晶体形式 |
| US10253030B2 (en) | 2015-11-04 | 2019-04-09 | Qilu Pharmaceutical Co., Ltd. | Crystal form, preparation method and intermediate of dihydropyrido ring compound |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| SG11201807543YA (en) | 2016-03-07 | 2018-09-27 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| EP3458455B1 (en) | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| EP3484886B1 (en) | 2016-07-14 | 2020-03-04 | Hoffmann-La Roche AG | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011162A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| WO2018011160A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018052967A1 (en) | 2016-09-13 | 2018-03-22 | Arbutus Biopharma, Inc. | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same |
| JOP20190105A1 (ar) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
| MA49014A (fr) | 2017-03-21 | 2020-02-05 | Arbutus Biopharma Corp | Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant |
| KR20200083552A (ko) * | 2017-11-02 | 2020-07-08 | 아이쿠리스 게엠베하 운트 코. 카게 | B형 간염 바이러스 (hbv)에 활성인 신규 고활성 피라졸로-피페리딘 치환된 인돌-2-카르복스아미드 |
-
2018
- 2018-11-02 EA EA202091113A patent/EA202091113A1/ru unknown
- 2018-11-02 MA MA050524A patent/MA50524A/fr unknown
- 2018-11-02 WO PCT/EP2018/000502 patent/WO2019086141A1/en not_active Ceased
- 2018-11-02 GE GEAP202115351A patent/GEAP202115351A/en unknown
- 2018-11-02 CU CU2020000037A patent/CU20200037A7/es unknown
- 2018-11-02 JP JP2020524457A patent/JP2021501764A/ja active Pending
- 2018-11-02 AU AU2018361364A patent/AU2018361364B2/en not_active Ceased
- 2018-11-02 TW TW107139067A patent/TW201930315A/zh unknown
- 2018-11-02 MX MX2020004839A patent/MX2020004839A/es unknown
- 2018-11-02 BR BR112020008762-9A patent/BR112020008762A2/pt not_active IP Right Cessation
- 2018-11-02 US US16/761,189 patent/US11267825B2/en active Active
- 2018-11-02 AR ARP180103202A patent/AR113826A1/es unknown
- 2018-11-02 CA CA3081386A patent/CA3081386A1/en not_active Abandoned
- 2018-11-02 EP EP18811439.1A patent/EP3704127A1/en not_active Withdrawn
- 2018-11-02 SG SG11202003700TA patent/SG11202003700TA/en unknown
- 2018-11-02 KR KR1020207015662A patent/KR20200083551A/ko not_active Ceased
- 2018-11-02 CN CN201880079554.1A patent/CN111448199A/zh active Pending
- 2018-11-02 GE GEAP201815351A patent/GEP20227373B/en unknown
- 2018-11-05 UY UY0001037962A patent/UY37962A/es not_active Application Discontinuation
-
2020
- 2020-04-27 IL IL274298A patent/IL274298A/en unknown
- 2020-04-30 PH PH12020550525A patent/PH12020550525A1/en unknown
- 2020-04-30 CL CL2020001145A patent/CL2020001145A1/es unknown
- 2020-05-04 ZA ZA2020/02249A patent/ZA202002249B/en unknown
- 2020-06-01 EC ECSENADI202029558A patent/ECSP20029558A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2020001145A1 (es) | 2020-10-09 |
| WO2019086141A8 (en) | 2019-08-29 |
| BR112020008762A2 (pt) | 2020-10-20 |
| WO2019086141A1 (en) | 2019-05-09 |
| GEAP202115351A (en) | 2021-12-10 |
| GEP20227373B (en) | 2022-04-25 |
| MA50524A (fr) | 2020-09-09 |
| IL274298A (en) | 2020-06-30 |
| MX2020004839A (es) | 2020-10-16 |
| US20200354379A1 (en) | 2020-11-12 |
| EP3704127A1 (en) | 2020-09-09 |
| JP2021501764A (ja) | 2021-01-21 |
| SG11202003700TA (en) | 2020-05-28 |
| AU2018361364A1 (en) | 2020-05-21 |
| TW201930315A (zh) | 2019-08-01 |
| CU20200037A7 (es) | 2021-03-11 |
| EA202091113A1 (ru) | 2020-08-28 |
| AU2018361364B2 (en) | 2020-11-26 |
| CN111448199A (zh) | 2020-07-24 |
| ZA202002249B (en) | 2022-01-26 |
| UY37962A (es) | 2019-05-31 |
| CA3081386A1 (en) | 2019-05-09 |
| ECSP20029558A (es) | 2020-07-31 |
| KR20200083551A (ko) | 2020-07-08 |
| US11267825B2 (en) | 2022-03-08 |
| PH12020550525A1 (en) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR113826A1 (es) | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| AR106605A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
| AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
| AR109349A1 (es) | Compuestos y usos | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| JP2016536364A5 (es) | ||
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| ES2659222T3 (es) | 7-azabicíclicos sustituidos y su uso para moduladores de receptores de orexina | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| JP2016536363A5 (es) | ||
| AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| JP2016540742A5 (es) | ||
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| JP2013510825A5 (es) | ||
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR101483A1 (es) | COMPUESTOS DE TIAZIN-2-AMINA FUSIONADOS CON CICLOPROPILO COMO INHIBIDORES DE b-SECRETASA Y MÉTODOS DE USO | |
| AR116947A1 (es) | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |